Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

BACKGROUND: Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations are common in acute myeloid leukemia (AML) and are associated with rapid relapse and short survival. In relapsed/refractory (R/R) AML, the clinical benefit of FLT3 inhibitors has been limited by rapid generation...

詳細記述

保存先:
書誌詳細
出版年:Lancet Oncol
主要な著者: Perl, Alexander E., Altman, Jessica K., Cortes, Jorge, Smith, Catherine, Litzow, Mark, Baer, Maria R., Claxton, David, Erba, Harry P., Gill, Stan, Goldberg, Stuart, Jurcic, Joseph G., Larson, Richard A., Liu, Chaofeng, Ritchie, Ellen, Schiller, Gary, Spira, Alexander I., Strickland, Stephen A., Tibes, Raoul, Ustun, Celalettin, Wang, Eunice S., Stuart, Robert, Röllig, Christoph, Neubauer, Andreas, Martinelli, Giovanni, Bahceci, Erkut, Levis, Mark
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572576/
https://ncbi.nlm.nih.gov/pubmed/28645776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30416-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料